Custom Antibody Production with Guaranteed Success

The binding affinity and specificity are the key indicators of a successful antibody. The majority of existing antibodies were raised against either full-length protein antigens (>200 amino acids) or long-peptide (>20 amino acids) antigens. Full-length protein antigens often cause promiscuous bindings in antibody due to the large number of potential binding sites. Long peptides are very difficult to dissolve into water even in the presence of DMSO. They must be denatured prior to conjugation to carrier proteins, which is the major cause of non-specific or off-target binding. BiCell Scientific^® researchers have discovered that short-peptide antigens (13-19 amino acids) allow developing polyclonal and monoclonal antibodies with specific and bona fide binding to target proteins in their native conformation. This feature is particularly important for immunohistochemistry studies that require undenatured proteins to be recognized. Short antigen sequences also allow antibodies to be used in protein domain specific or amino acid site specific recognition. Custom ordering polyclonal antibodies takes 7-12 weeks depending upon antigen sequence. Target proteins will be analyzed by advanced algorithms based upon DeepMind's AlphaFold protein structures to facilitate the rational design of peptide antigens. Short peptide antigens (13-19 amino acid long) ensures high specificity of antibody binding and allows developing site-specific antibodies that can recognize point mutation, phosphorylation, acetylation, methylation and many other forms of modification in target proteins. Custom ordered antibodies will be manufactured, purified and validated against human or rodent tissues using ELISA and immunofluorescence labeling techniques. Successful binding signals are guaranteed. Projects that fail to produce meaningful binding signals will be fully refunded. Custom ordering monoclonal antibodies takes 3-5 months depending upon antigen sequence. Target proteins will be analyzed by advanced algorithms to facilitate the rational design of peptide antigens. An antigen binding assay will be implemented to screen for the antibody secreting hybridoma cells. Both recombinant full-length protein antigen and short peptide antigen can be used to make monoclonal antibody. Short peptide antigens also allow making site-specific monoclonal antibodies. Custom ordered antibodies will be manufactured, purified and validated against human or rodent tissues using ELISA and immunofluorescence labeling techniques. One validated hybridoma cell line will be provided in addition to the purified antibody. Successful binding signals are guaranteed. Projects that fail to produce meaningful binding signals will be fully refunded. Protein modifications that can be targeted for site specific polyclonal or monoclonal antibody production:         – Acetylation;   Cleavage sites;   Drug binding Isoforms;   Glycosylation;   Ligand binding;   Myristolation;            – Phosphorylation;   Prenylation;   Splice variants;   Sumoylation;   Ubiquitination;   Mutations/Polymorphisms. All animal work is performed at St Louis University Department of Comparative Medicine and approved by IACUC under animal use protocol number AUP #2943.